Abstract Library

#4207 START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors – An open-label, multi-center, randomised phase III trial comparing safety and efficacy of personalised vs non-personalised radionuclide therapy with 177Lu-DOTATOC

Introduction: Peptide receptor radionuclide therapy (PRRT) with fixed activity dosing is an established treatment for advanced neuroendocrine tumors (NETs). Emerging data suggest that patients may benefit from a personalized treatment approach. Aggressive NET is believed to benefit from more intensive treatment, one example being FDG-PET positive tumors have shown benefit from combining PPRT with chemotherapy. Dosimetry is another means of achieving personalisation and can be used to increase the tumor radiation doses without surpassing the toxicity limits of organs at risk.

Conference:

Presenting Author: Asp P

Authors: Asp P, Sjögreen-Gleisner K, Fröss-Baron K, Sandström M, Hallqvist A,

Keywords: NET, PRRT, dosimetry, PET, 177Lu-DOTATOC, capecitabine,

#3816 MET exon 14 skipping mutation – A new potential therapeutical target for lung carcinoids? Results from a next-generation sequencing (NGS) study

Introduction: Lung NETs, classified as typical carcinoid (TC) and atypical carcinoid (AC), share the well-differentiated morphology, but are characterized by an extreme heterogeneity in terms of biological aggressiveness and outcomes. Unfortunately, to date a unique molecular classification of these tumors is lacking, and therefore no personalized treatments are available.

Conference:

Presenting Author: La Salvia A

Authors: La Salvia A, Melucci E, Ciuffreda L, Resuli B, Visca P,

Keywords: lung neuroendocrine tumor, molecular profile, Oncomine Focus panel, MET exon 14 skipping mutation, therapeutic target,

#3530 Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: The Gustave Roussy experience

Introduction: Key molecular alterations (MA) of neuroendocrine neoplasm (NEN) of various grade/primaries have been described but the applicability of molecular profiling (MP) for precision medicine (PM) in NEN remains to be demonstrated.

Conference:

Presenting Author: Boilève A

Authors: Boilève A, Faron M, Bayle A, Mouren A, Lamartina L,

Keywords: Precision medicine, personalized treatment, neuroendocrine tumor, neuroendocrine carcinoma, molecular profile,

#2995 Prediction of Symptomatic Mesenteric Mass in Patients with Small Intestinal Neuroendocrine Tumors Using a CT Radiomics Approach

Introduction: A mesenteric mass surrounded by fibrosis is a hallmark feature of small intestinal neuroendocrine tumors (SI-NETs) that can induce severe abdominal complications. To improve clinical outcome, there is a need for personalized treatment strategies based on accurate prediction of development of abdominal complications.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Blazevic A

Authors: Blazevic A, Starman M, Brabander T, Hofland J, Franssen G,

Keywords: Small-intestinal neuroendocrine tumors, mesenteric mass, mesenteric fibrosis, radiomics, CT scan,

#1914 Prognostic Factors for Long-Term Survival in 102 Consecutive Pancreatic Resections for Primary Neuroendocrine Tumor

Introduction: Neuroendocrine tumors (NET) of the pancreas represent a rare entity of primary pancreatic tumors. However, with the continuous progress in modern diagnostics NET`s are increasingly detected and prognostic factors are being reevaluated to establish personalized treatment concepts.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Klein F, Bahra M, Pratschke J, Pavel M, Pape U,

Keywords: NET, pancreas, surgery,